{
    "clinical_study": {
        "@rank": "1699", 
        "brief_summary": {
            "textblock": "The purpose of this study is to see if it is safe and effective to give ritonavir plus\n      nelfinavir to HIV-infected patients.  This study will also see how ritonavir and nelfinavir\n      are absorbed by the body and how they affect the level of HIV in the blood."
        }, 
        "brief_title": "A Study of Ritonavir (ABT-538) When Used With Nelfinavir in HIV-Infected Patients", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  Documentation of a positive ELISA test for HIV confirmed by immunoblot, or a positive\n             HIV RNA test using the Roche PCR assay, or the Chiron bDNA assay.\n\n          -  HIV RNA measurement of > 5,000 copies/ml within 3 weeks of baseline visit.\n\n          -  Signed, informed consent from parent or legal guardian for patients less than 18\n             years of age.\n\n          -  Access to a refrigerator for storing study drug.\n\n        Prior Medication:\n\n        Allowed:\n\n        Anti-HIV therapy other than protease inhibitor therapy.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following conditions or symptoms are excluded:\n\n          -  Evidence of acute infection, as measured by vital signs, physical examination,\n             12-lead electrocardiogram and laboratory assessments.\n\n          -  Condition that may obscure the proper observation of the safety or activity of the\n             treatment regimens.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Midazolam, alprazolam, clorazepate, diazepam, estazolam, flurazepam, triazolam,\n             zolpidem, quinidine, amiodarone, encainide, flecainide, propafenone, bepridil,\n             terfenadine, astemizole, cisapride, bupropion, clozapine, rifabutin, meperidine,\n             propoxyphene, piroxicam, pimozide, ergotamine, dihydroergotamine, and rifampin.\n\n          -  Anti-retroviral therapy initiated prior to study entry.\n\n          -  Any other medication, including over-the-counter medicine and alcohol, taken without\n             the permission of the primary investigator.\n\n        Patients with the following prior conditions are excluded:\n\n          -  History of significant drug hypersensitivity.\n\n          -  History of psychiatric illness that would preclude compliance with the protocol.\n\n          -  Prior enrollment in this study.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Investigational drugs within 30 days prior to drug administration.\n\n          -  Prior treatment with licensed or investigational HIV protease inhibitor.\n\n             1. Active substance abuse.\n\n          -  Positive urine screen for recreational drugs. NOTE:\n\n          -  The presence of cannabis is not exclusionary unless the investigator believes its use\n             will interfere with patient compliance."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "12 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002201", 
            "org_study_id": "245D", 
            "secondary_id": "M96-581"
        }, 
        "intervention": [
            {
                "intervention_name": "Ritonavir", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Nelfinavir mesylate", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "HIV Protease Inhibitors", 
                "Ritonavir", 
                "Nelfinavir"
            ]
        }, 
        "keyword": [
            "Drug Therapy, Combination", 
            "HIV Protease Inhibitors", 
            "Ritonavir", 
            "Nelfinavir", 
            "Anti-HIV Agents"
        ], 
        "lastchanged_date": "February 19, 2009", 
        "location": {
            "facility": {
                "address": {
                    "city": "Baltimore", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "21287"
                }, 
                "name": "Johns Hopkins Hosp"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Safety and Efficacy of Ritonavir (ABT-538) in Combination With Nelfinavir in HIV-Infected Subjects.", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "reference": {
            "PMID": "11114832", 
            "citation": "Raines CP, Flexner C, Sun E, Heath-Chiozzi M, Lewis RH, Fields C, Deetz C, Apuzzo L, Eshleman SH, Jackson JB, Gallant JE. Safety, tolerability, and antiretroviral effects of ritonavir-nelfinavir combination therapy administered for 48 weeks. J Acquir Immune Defic Syndr. 2000 Dec 1;25(4):322-8."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002201"
        }, 
        "source": "Abbott", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Abbott", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Pharmacodynamics Study, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2009"
    }, 
    "geocoordinates": {
        "Johns Hopkins Hosp": "39.29 -76.612"
    }
}